Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.4900 (-6.31%) ($5.4900 - $5.4900) on Tue. May. 4, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.02% (three month average) | RSI | 66 | Latest Price | $5.4900(-6.31%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -1.2% a day on average for past five trading days. | Weekly Trend | ADMS advances 5.4% a week on average for past two weeks. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) TIP(74%) EWG(32%) UNG(24%) EWP(22%) IBUY(15%) | Factors Impacting ADMS price | ADMS will decline at least -2.01% in a week (0% probabilities). UUP(-52%) TLT(-31%) FXI(-25%) MCHI(-16%) LQD(-11%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.01% (StdDev 4.02%) | Hourly BBV | -1.2 () | Intraday Trend | 0% | | | |
|
5 Day Moving Average | $5.69(-3.51%) | 10 Day Moving Average | $5.62(-2.31%) | 20 Day Moving Average | $5.26(4.37%) | To recent high | -13.8% | To recent low | 9.4% | Market Cap | $155m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |